open access

Vol 50, No 4 (2012)
Original paper
Submitted: 2012-12-23
Accepted: 2012-12-23
Published online: 2012-12-23
Get Citation

Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients

Magdalena Groblewska, Barbara Mroczko, Miroslaw Kozlowski, Jacek Niklinski, Jerzy Laudanski, Maciej Szmitkowski
DOI: 10.5603/FHC.2012.0083
·
Folia Histochem Cytobiol 2012;50(4):590-598.

open access

Vol 50, No 4 (2012)
ORIGINAL PAPERS
Submitted: 2012-12-23
Accepted: 2012-12-23
Published online: 2012-12-23

Abstract

The positive expression of MMP-2 and TIMP-2 were found in esophageal cancer (EC) tissue and
correlated with cancer stage and clinico-pathological features of tumor and patients’ survival. However, little is
known about serum levels of those proteins in EC patients. The aim of the present study was to investigate the
diagnostic significance of MMP-2 and TIMP-2 serum levels in EC patients in relation to clinico-pathological
features of cancer. The study included 53 EC patients and 92 healthy controls. The serum levels of MMP-2,
TIMP-2 and classical tumor markers CEA (carcinoembryonic antigen) and SCC (squamous cell carcinoma
antigen) were assayed. The prognostic values and diagnostic criteria for the biomarkers tested were defined.
Serum levels of MMP-2, TIMP-2 in EC patients were significantly lower, whereas CEA and SCC significantly
higher than in control group. The diagnostic sensitivity of TIMP-2 (57%) was higher than those for other biomarkers
tested and increased in combination with SCC (70%). Area under ROC curve for TIMP-2 (0.8698) was
larger than for other proteins. In Cox’s univariate analysis only SCC serum levels were significant prognostic
factors for EC patients’ survival. The results suggest the limited value of serum analyses of MMP-2 for tumor
staging and prognosis in EC and the better usefulness of TIMP-2 than MMP-2 as a tumor marker in the diagnosis
of EC, especially in combined use with SCC.

Abstract

The positive expression of MMP-2 and TIMP-2 were found in esophageal cancer (EC) tissue and
correlated with cancer stage and clinico-pathological features of tumor and patients’ survival. However, little is
known about serum levels of those proteins in EC patients. The aim of the present study was to investigate the
diagnostic significance of MMP-2 and TIMP-2 serum levels in EC patients in relation to clinico-pathological
features of cancer. The study included 53 EC patients and 92 healthy controls. The serum levels of MMP-2,
TIMP-2 and classical tumor markers CEA (carcinoembryonic antigen) and SCC (squamous cell carcinoma
antigen) were assayed. The prognostic values and diagnostic criteria for the biomarkers tested were defined.
Serum levels of MMP-2, TIMP-2 in EC patients were significantly lower, whereas CEA and SCC significantly
higher than in control group. The diagnostic sensitivity of TIMP-2 (57%) was higher than those for other biomarkers
tested and increased in combination with SCC (70%). Area under ROC curve for TIMP-2 (0.8698) was
larger than for other proteins. In Cox’s univariate analysis only SCC serum levels were significant prognostic
factors for EC patients’ survival. The results suggest the limited value of serum analyses of MMP-2 for tumor
staging and prognosis in EC and the better usefulness of TIMP-2 than MMP-2 as a tumor marker in the diagnosis
of EC, especially in combined use with SCC.
Get Citation
About this article
Title

Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 50, No 4 (2012)

Article type

Original paper

Pages

590-598

Published online

2012-12-23

DOI

10.5603/FHC.2012.0083

Bibliographic record

Folia Histochem Cytobiol 2012;50(4):590-598.

Authors

Magdalena Groblewska
Barbara Mroczko
Miroslaw Kozlowski
Jacek Niklinski
Jerzy Laudanski
Maciej Szmitkowski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl